OBJECTIVE: To review the currently available data to investigate the clinical benefit of high- and low-dose glucose-insulin-potassium (GIK) in patients with ST-segment elevation acute myocardial infarction (STEMI). DESIGN: Quantitative analysis of all randomised trials on GIK in patients with STEMI. Electronic and manual searches for randomised controlled trials of GIK in STEMI were performed with regard to inclusion criteria, dose of GIK and additional use of reperfusion therapy, and a meta-analysis with the primary endpoint 30-day mortality was performed. PATIENTS: Data from 16 randomised trials, involving 26,273 patients, were included. RESULTS: Studies were conducted between 1962 and 2005. Overall, hospital mortality was 9.6% after GIK compared with 10.2% in controls (p=0.088). GIK infusion was not associated with an increase in major adverse events. CONCLUSION: This quantitative analysis of GIK in patients with STEMI did not show a beneficial or detrimental effect of GIK infusion on 30-day mortality. GIK infusion should not be part of the standard therapy for patients with STEMI.
OBJECTIVE: To review the currently available data to investigate the clinical benefit of high- and low-dose glucose-insulin-potassium (GIK) in patients with ST-segment elevation acute myocardial infarction (STEMI). DESIGN: Quantitative analysis of all randomised trials on GIK in patients with STEMI. Electronic and manual searches for randomised controlled trials of GIK in STEMI were performed with regard to inclusion criteria, dose of GIK and additional use of reperfusion therapy, and a meta-analysis with the primary endpoint 30-day mortality was performed. PATIENTS: Data from 16 randomised trials, involving 26,273 patients, were included. RESULTS: Studies were conducted between 1962 and 2005. Overall, hospital mortality was 9.6% after GIK compared with 10.2% in controls (p=0.088). GIK infusion was not associated with an increase in major adverse events. CONCLUSION: This quantitative analysis of GIK in patients with STEMI did not show a beneficial or detrimental effect of GIK infusion on 30-day mortality. GIK infusion should not be part of the standard therapy for patients with STEMI.
Authors: L Marano; A Bestetti; A Lomuscio; L Tagliabue; D Castini; D Tarricone; P Dario; G L Tarolo; C Fiorentini Journal: Acta Cardiol Date: 2000-02 Impact factor: 1.718
Authors: Iwan C C van der Horst; Felix Zijlstra; Arnoud W J van 't Hof; Carine J M Doggen; Menko-Jan de Boer; Harry Suryapranata; Jan C A Hoorntje; Jan-Henk E Dambrink; Rijk O B Gans; Henk J G Bilo Journal: J Am Coll Cardiol Date: 2003-09-03 Impact factor: 24.094